Aurinia Pharmaceuticals Inc. Submits IND Application to US F

Aurinia Pharmaceuticals Inc. announced the submission of its Investigational New Drug application to the U.S. Food and Drug Administration for AUR200, a potential next generation therapy for B-cell...

Related Keywords

, Drug Administration , Aurinia Pharmaceuticals Inc , American College Of Rheumatology Convergence , Aurinia Pharmaceuticals , Investigational New Drug , B Cell Activating Factor , Proliferation Inducing Ligand , American College , Rheumatology Convergence , Markets ,